{"result": "(\"entity\"<|>LA FE HOSPITAL UNIVERSITARI I POLITÈCNIC<|>ORGANIZATION<|>La Fe Hospital Universitari i Politècnic is a healthcare institution involved in the treatment and management of thrombotic conditions.)\n##\n(\"entity\"<|>TROMBOLISIS<|>EVENT<|>Trombolysis is a medical procedure aimed at dissolving blood clots in patients, with specific efficacy rates and indications for use.)\n##\n(\"entity\"<|>HEPARINIZACIÓN<|>EVENT<|>Heparinization refers to the administration of low molecular weight heparins for the treatment and prophylaxis of thrombotic events.)\n##\n(\"entity\"<|>TROMBOSIS<|>EVENT<|>Thrombosis is a medical condition characterized by the formation of a blood clot within a blood vessel, which can lead to serious health complications.)\n##\n(\"entity\"<|>ANTICOAGULACIÓN<|>EVENT<|>Anticoagulation is a fundamental treatment approach for patients with thrombotic conditions, involving the use of medications to prevent blood clot formation.)\n##\n(\"relationship\"<|>LA FE HOSPITAL UNIVERSITARI I POLITÈCNIC<|>TROMBOLISIS<|>La Fe Hospital Universitari i Politècnic provides treatment involving thrombolysis for patients with thrombotic conditions.<|>7)\n##\n(\"relationship\"<|>LA FE HOSPITAL UNIVERSITARI I POLITÈCNIC<|>HEPARINIZACIÓN<|>La Fe Hospital Universitari i Politècnic administers heparinization as part of its treatment protocols for thrombotic patients.<|>7)\n##\n(\"relationship\"<|>TROMBOLISIS<|>TROMBOSIS<|>Trombolysis is a procedure used to treat thrombosis by dissolving blood clots.<|>8)\n##\n(\"relationship\"<|>HEPARINIZACIÓN<|>TROMBOSIS<|>Heparinization is a treatment method used to manage and prevent thrombosis in patients.<|>8)\n##\n(\"relationship\"<|>ANTICOAGULACIÓN<|>TROMBOSIS<|>Anticoagulation is a key treatment strategy for managing thrombosis and preventing further clot formation.<|>9)\n##\n(\"relationship\"<|>ANTICOAGULACIÓN<|>HEPARINIZACIÓN<|>Anticoagulation includes the use of heparinization as a method to prevent and treat thrombotic events.<|>8)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: empleará también para control y seguimiento.\n- Cateterografía: valorar existencia, ubicación y extensión de trombo.\n- Estudio Trombofilia: cuando la trombosis es espontánea, de gravedad desproporcionada, recurrente, de localización inusual, o cuando existe historia familiar. Excluir: deficiencia de inhibidores naturales de la coagulación (proteína C, S, AT-III), resistencia a la proteína C activada (mutación del factor V, conocida como factor Leyden), mutación del gen de la protrombina (G20210A) y anomalías del sistema fibrinolítico (t-PA, PAI, plasminógeno, homocisteína).\n\n### TRATAMIENTO / MANEJO:\n\nLa anticoagulación es el pilar fundamental del tratamiento en estos pacientes, estando indicada la trombolisis sólo en circunstancias muy concretas.\n\nTROMBOLISIS:\n\nEficacia con resolución completa o apertura del flujo sanguíneo en 65-81% y parcial en el 14-20%. Se recomienda no demorar su inicio más de 72 horas.\n\n- Indicaciones consistentes: Trombos que amenazan vida/miembro/órgano, como son los trombos arteriales o venosos que causan isquemia, síndrome de vena cava superior, tromboembolismo pulmonar con inestabilidad hemodinámica, trombosis renal bilateral, trombosis seno venoso con deterioro neurológico, trombo grande en aurícula, alteraciones congénitas cardiacas con shunt.\n---\n• Indicaciones intermedias: trombos con obstrucción extensa ileofemoral /cava inferior, especialmente si DD ≥500 mg/dl o elevación FVIII ≥150 U/dl y aparición aguda.\n\n• Contraindicaciones: cirugía mayor en los últimos 7-10 días, sangrado activo, cirugía/trauma/sangrado/isquemia en SNC en los últimos 30 días, convulsiones en las últimas 48 horas, imposibilidad para mantener plaquetas > 75.000 y fibrinógeno > 100 mg/dl, HTA incontrolada.\n\n• Posología: Urokinasa (vida media 15 minutos): bolo de 4400 U/kg a pasar en 10-20 minutos y posteriormente mantenimiento: 4400 U/kg/hora, durante 12-24-48 horas.\n\n• Controles: antes del inicio (TT, fibrinógeno, Dímeros D, PDF y plaminógeno), PDF o DD a la media hora de iniciado y fibrinógeno y TT cada 6 hora\n\n• Neutralización: En caso de hemorragia leve (superficies cutáneas, epistaxis) se trata con medidas locales. Si no cede o es importante y el fibrinógeno ha descendido por debajo de 80mg, se administra concentrado de fibrinógeno o crioprecipitado (1 unidad/5kg) y si además tiene riesgo vital se revierte el efecto del trombolítico con antifibrinolítico.\n\n## HEPARINIZACIÓN:\n\nSe realizará con Heparinas de bajo Peso Molecular (HBPM):\n\n| Edad (meses) | Dosis de tratamiento | Dosis de profilaxis |\n|--------------|----------------------|---------------------|\n| <2 meses | 1.5 mg/kg cada 12 horas sc | 0.75 mg/kg cada 12 horas sc |\n| >2 meses | 1.0 mg/kg cada 12 horas sc | 0.5 mg/kg cada 12 horas sc |\n\nMáximo: 2 mg/kg cada 12 horas\n\n• Controles: HMG completo y coagulación con DD, antiXa semanal (4-6 horas tras administración sc de HBPM; niveles terapéuticos de antiXa : 0.5-1 U/mL).En tratamientos prolongados realizar densitometría ósea basal y a los 6 meses .\n---\n| Niveles antiXa (unidad/mL) | dosis |\n|---------------------------|-------|\n| <0.35 | Incrementar 25% |\n| <0.5 | Incrementar 10% |\n| 0.5-1 | NO cambios |\n| >1.0 | Reducir 20% |\n| >1.5 | Reducir 30% |\n| >2.0 | Suspender durante 24 horas |\n\n- Neutralización: Con frecuencia interrumpir HBMP es suficiente. Si se precisa efecto inmediato: 1 mg Protamina (iv, en 10 minutos) por cada 100 unidades (1 mg) de HBPM.\n\n- Duración tratamiento: 7-10 días (valorar más tiempo si el territorio es muy extenso).\n\n- Duración de profilaxis con HBPM: 1- 3 meses, INDIVIDUALIZADO. Misma dosis que durante el tratamiento pero cada 24 horas.\n\n[A logo at the bottom of the image reads \"La Fe Hospital Universitari i Politècnic\"]\n\n288\n---\nEsquema 2: Manejo de la obstrucción trombótica extraluminal\n\n```mermaid\ngraph TD\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}